What is "menafrivac"

MenAfriVac is a vaccine developed for use in sub-Saharan Africa that protects infants under one year old to people up to 29 years of age against meningococcal bacterium Neisseria meningitidis group A. MenAfriVac costs under US$0.50 per dose and reduces transmission of the bacteria between people. The Meningitis Vaccine Project, a partnership between the Program for Appropriate Technology in Health (PATH) and the World Health Organization, worked with a consortium of international partners to develop the vaccine.